1
|
Manahan GG, Habib AF, Scherkl P, Ullmann D, Beaton A, Sutherland A, Kirwan G, Delinikolas P, Heinemann T, Altuijri R, Knetsch A, Karger O, Cook NM, Bruhwiler DL, Sheng ZM, Rosenzweig JB, Hidding B. Advanced schemes for underdense plasma photocathode wakefield accelerators: pathways towards ultrahigh brightness electron beams. Philos Trans A Math Phys Eng Sci 2019; 377:20180182. [PMID: 31230572 PMCID: PMC6602916 DOI: 10.1098/rsta.2018.0182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 04/18/2019] [Indexed: 06/09/2023]
Abstract
The 'Trojan Horse' underdense plasma photocathode scheme applied to electron beam-driven plasma wakefield acceleration has opened up a path which promises high controllability and tunability and to reach extremely good quality as regards emittance and five-dimensional beam brightness. This combination has the potential to improve the state-of-the-art in accelerator technology significantly. In this paper, we review the basic concepts of the Trojan Horse scheme and present advanced methods for tailoring both the injector laser pulses and the witness electron bunches and combine them with the Trojan Horse scheme. These new approaches will further enhance the beam qualities, such as transverse emittance and longitudinal energy spread, and may allow, for the first time, to produce ultrahigh six-dimensional brightness electron bunches, which is a necessary requirement for driving advanced radiation sources. This article is part of the Theo Murphy meeting issue 'Directions in particle beam-driven plasma wakefield acceleration'.
Collapse
Affiliation(s)
- G. G. Manahan
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
| | - A. F. Habib
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
| | - P. Scherkl
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
| | - D. Ullmann
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
| | - A. Beaton
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
| | - A. Sutherland
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
| | - G. Kirwan
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - P. Delinikolas
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
| | - T. Heinemann
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - R. Altuijri
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
- Physics Department, Princess Nora Bint Abd Ulrahman University, Riyadh, Kingdom of Saudi Arabia
| | - A. Knetsch
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - O. Karger
- Department of Experimental Physics, University of Hamburg, Hamburg, Germany
| | | | | | - Z.-M. Sheng
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
- Laboratory for Laser Plasmas and School of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai, People's Republic of China
| | - J. B. Rosenzweig
- Particle Beam Physics Laboratory, University of California, Los Angeles, CA, USA
| | - B. Hidding
- Scottish Universities Physics Alliance, Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
- Cockcroft Institute, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4AD, UK
| |
Collapse
|
2
|
Smith YE, Toomey S, Napoletano S, Kirwan G, Schadow C, Chubb AJ, Mikkelsen JH, Oxvig C, Harmey JH. Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer. BMC Cancer 2018; 18:1016. [PMID: 30348128 PMCID: PMC6196427 DOI: 10.1186/s12885-018-4950-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Accepted: 10/15/2018] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The Insulin-like growth factor (IGF) pathway plays a role in tumour development and progression. In vivo, IGF1 activity is regulated by the IGF binding proteins (IGFBPs). IGFBP4 inhibits the activity of IGF1 but proteolytic cleavage by pregnancy-associated plasma protein-A (PAPP-A) releases active IGF1. A modified IGFBP4, dBP4, which was resistant to PAPP-A cleavage but retained IGF1 binding capacity, was engineered, expressed in Human Embryonic Kidney (HEK) 293 cells and purified. This study examined the effects of dBP4 on IGF1-induced cell migration, invasion and angiogenesis in vitro. The effect of intra-tumour injections of dBP4 on tumour angiogenesis and metastasis was examined using the 4T1.2luc orthotopic model of breast cancer. METHODS PAPP-A resistance and IGF binding capacity of dBP4 were characterized by Western blot and surface plasmon resonance, respectively. 4T1.2luc are mouse mammary adenocarcinoma cells transfected with luciferase to allow in vivo imaging. The effect of dBP4 on IGF1-induced Akt activation in 4T1.2luc cells was assessed by Western blot. Cell migration and invasion assays were performed using 4T1.2luc cells. Angiokit™ assays and Matrigel® implants were used to assess the effects of dBP4 on angiogenesis in vitro and in vivo, respectively. An orthotopic breast cancer model - 4T1.2luc cells implanted in the mammary fat pad of BALB/c mice - was used to assess the effect of intra tumour injection of purified dBP4 on tumour angiogenesis and metastasis. Tumour growth and lung metastasis were examined by in vivo imaging and tumour angiogenesis was evaluated by CD31 immunohistochemistry. RESULTS Our engineered, PAPP-A resistant IGFBP4 (dBP4) retained IGF1 binding capacity and inhibited IGF1 activation of Akt as well as IGF1-induced migration and invasion by 4T1.2 mammary adenocarcinoma cells. dBP4 inhibited IGF1-induced angiogenesis in vitro and in Matrigel implants in vivo. Direct intra-tumour injection of soluble dBP4 reduced angiogenesis in 4T1.2 luc mammary tumours tumour and reduced lung metastasis. CONCLUSION A PAPP-A resistant IGFBP4, dBP4, inhibits angiogenesis and metastasis in 4T1.2 mammary fat pad tumours. This study highlights the therapeutic potential of dBP4 as an approach to block the tumour-promoting actions of IGF1.
Collapse
Affiliation(s)
- Y E Smith
- Angiogenesis and Metastasis Research, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland
| | - S Toomey
- Angiogenesis and Metastasis Research, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland
| | - S Napoletano
- Angiogenesis and Metastasis Research, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland
| | - G Kirwan
- Angiogenesis and Metastasis Research, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland
| | - C Schadow
- Angiogenesis and Metastasis Research, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland
| | - A J Chubb
- Angiogenesis and Metastasis Research, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland
| | - J H Mikkelsen
- Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 10C, 8000, Aarhus C, Denmark
| | - C Oxvig
- Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 10C, 8000, Aarhus C, Denmark
| | - J H Harmey
- Angiogenesis and Metastasis Research, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.
| |
Collapse
|